Has Lindsey Greene received payments from drug or device companies?

Yes. Drug and device makers reported $89,683 in general payments to Lindsey Greene across 68 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lindsey Greene did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lindsey Greene come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lindsey Greene

Pediatric Hematology-Oncology · Philadelphia, PANPI 1689827073

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $64,844 of the $89,683 with a category attached, or 72.3%. 8 manufacturers reported payments, led by CSL Behring at 38.4% of the total. 2025 is the largest year on record at $27,157, more than ten times the $91 reported in 2019. Among pediatric hematology-oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,683in general payments, 2019–2025

Across 68 payments — averaging $1318.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

CSL Behring$34K
Pfizer$18K
Regeneron$15K
Spark Therapeutics, Inc.$14K
F. Hoffmann-la Roche AG$4K
Biomarin Pharmaceutical Inc.$2K
plus $2K from 2 others

$566,329in research payments, 2019–2025

Across 85 payments — averaging $6662.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Spark Therapeutics, Inc.$432K
Pfizer$134K

What the payments were for

Consulting fees$64,84472%
Speaking & faculty fees$16,68819%
Travel & lodging$6,5797%
Food & beverage$9141%
Education$6591%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
CSL Behring	24	$34,478
Pfizer	12	$17,991
Regeneron	13	$14,950
Spark Therapeutics, Inc.	12	$14,314
F. Hoffmann-la Roche AG	2	$4,157
Biomarin Pharmaceutical Inc.	1	$2,100
Takeda Pharmaceuticals U.S.A., Inc.	1	$1,600
Bayer	3	$91

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

HEMGENIX$23,032
Idelvion$10,416
HEMLIBRA$4,100
ADVATE$1,600

How this compares

$89,683 in reported general payments places this provider in the 90th percentile of 139 pediatric hematology-oncology providers in Pennsylvania.

See all pediatric hematology-oncology providers in Pennsylvania →

Other pediatric hematology-oncology in Philadelphia

Stephan GruppPhiladelphia$390K
Samuel BlackmanPhiladelphia$265K
Sarah TasianPhiladelphia$90K
Janet KwiatkowskiPhiladelphia$65K
Katherine HighPhiladelphia$63K
Michele LambertPhiladelphia$62K
Nataly ApollonskyPhiladelphia$57K
Leslie RaffiniPhiladelphia$52K
Michael FisherPhiladelphia$45K
David TeacheyPhiladelphia$38K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →